- FDA advisory panel to consider OTC status of NSAIDs
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- FDA recommends health professionals prescribe no more than 325 mg of acetaminophen per dose
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
- Senate passes Drug Quality and Security Act
PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for arthritis made by Watson Pharmaceuticals, Watson said Friday.
The drug maker announced the approval of nabumetone tablets in the 500-mg and 750-mg strength. The drug is used to treat signs and symptoms of rheumatoid arthritis and osteoarthritis.
Nabumetone had sales of $58 million during the 12-month period ended in April, according to IMS Health.